{"id":50603,"date":"2022-11-08T13:02:22","date_gmt":"2022-11-08T12:02:22","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/koru-medical-systems-announces-novel-therapy-collaboration-for-three-indications-with-kira-pharmaceuticals\/"},"modified":"2022-11-08T13:02:22","modified_gmt":"2022-11-08T12:02:22","slug":"koru-medical-systems-announces-novel-therapy-collaboration-for-three-indications-with-kira-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/koru-medical-systems-announces-novel-therapy-collaboration-for-three-indications-with-kira-pharmaceuticals\/","title":{"rendered":"KORU Medical Systems Announces Novel Therapy Collaboration for Three Indications with Kira Pharmaceuticals"},"content":{"rendered":"
\n

MAHWAH, N.J.–(BUSINESS WIRE)–KORU Medical Systems, Inc. (NASDAQ: KRMD) (\u201cKORU Medical\u201d or the \u201cCompany\u201d),<\/b> a leading medical technology company focused on the development of innovative and easy-to-use subcutaneous infusion solutions, today announced the progression of its agreement with Kira Pharmaceuticals, including expansion into three important additional indications.\n<\/p>\n

\nKira will utilize KORU Medical\u2019s Freedom System for Phase II studies of Kira\u2019s lead program, KP-104, an innovative, first-in-class bifunctional complement inhibitor, in three indications. These diseases, collectively affecting over 150,000 patients in the United States and estimated hundreds of thousands more globally, consist of nephrology conditions IgA Neuropathy (IgAN) and Complement 3 Glomerulopathy (C3G) and hematology condition Thrombotic Microangiopathy secondary to Systemic Lupus Erythematosus (SLE-TMA). The expanded Kira partnership reflects the previously announced collaboration with an unnamed partner for a single hematology indication.\n<\/p>\n

\n\u201cWe selected KORU Medical based on their track record of helping patients receive high-value therapeutics subcutaneously in the comfort of their home,\u201d said Chaomei He, Kira\u2019s Head of Chemistry, Manufacturing, and Controls (CMC). \u201cThe Freedom System\u2019s ease of use, global regulatory approvals, experience with tens of thousands of patients, and ability to rapidly enter the clinic gave us confidence that KORU was the right partner for our KP-104 program.\u201d\n<\/p>\n

\n\u201cWe are privileged to work with Kira and help them achieve their mission of helping patients living with complement-mediated disease by providing treatment at home,\u201d said Linda Tharby, KORU Medical\u2019s President and CEO. \u201cThe expansion of our work with Kira and progression into Phase II studies is another important milestone in our strategy to grow our novel therapies pipeline in multiple therapeutic areas.\u201d\n<\/p>\n

\nAbout KORU Medical<\/strong>\n<\/p>\n

\nKORU Medical develops, manufactures, and commercializes innovative and easy-to-use subcutaneous infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System (the \u201cFreedom System\u201d) currently includes the FREEDOM60\u00ae<\/sup> and FreedomEdge\u00ae<\/sup> Syringe Infusion Drivers, Precision Flow Rate Tubing\u2122<\/sup> and HIgH-Flo Subcutaneous Safety Needle Sets\u2122<\/sup>. These devices are used for infusions administered in the home and alternate care settings. For more information, please visit www.korumedical.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Contact:<\/b>
Greg Chodaczek
\n
347-620-7010
\n
investor@korumedical.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MAHWAH, N.J.–(BUSINESS WIRE)–KORU Medical Systems, Inc. (NASDAQ: KRMD) (\u201cKORU Medical\u201d or the \u201cCompany\u201d), a leading medical technology company focused on the development of innovative and easy-to-use subcutaneous infusion solutions, today announced the progression of its agreement with Kira Pharmaceuticals, including expansion into three important additional indications. Kira will utilize KORU Medical\u2019s Freedom System for Phase … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50603","6":"format-standard","7":"category-industry"},"yoast_head":"\nKORU Medical Systems Announces Novel Therapy Collaboration for Three Indications with Kira Pharmaceuticals - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/koru-medical-systems-announces-novel-therapy-collaboration-for-three-indications-with-kira-pharmaceuticals\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"KORU Medical Systems Announces Novel Therapy Collaboration for Three Indications with Kira Pharmaceuticals - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MAHWAH, N.J.–(BUSINESS WIRE)–KORU Medical Systems, Inc. (NASDAQ: KRMD) (\u201cKORU Medical\u201d or the \u201cCompany\u201d), a leading medical technology company focused on the development of innovative and easy-to-use subcutaneous infusion solutions, today announced the progression of its agreement with Kira Pharmaceuticals, including expansion into three important additional indications. Kira will utilize KORU Medical\u2019s Freedom System for Phase ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/koru-medical-systems-announces-novel-therapy-collaboration-for-three-indications-with-kira-pharmaceuticals\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-08T12:02:22+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/koru-medical-systems-announces-novel-therapy-collaboration-for-three-indications-with-kira-pharmaceuticals\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/koru-medical-systems-announces-novel-therapy-collaboration-for-three-indications-with-kira-pharmaceuticals\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"KORU Medical Systems Announces Novel Therapy Collaboration for Three Indications with Kira Pharmaceuticals\",\"datePublished\":\"2022-11-08T12:02:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/koru-medical-systems-announces-novel-therapy-collaboration-for-three-indications-with-kira-pharmaceuticals\\\/\"},\"wordCount\":367,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/koru-medical-systems-announces-novel-therapy-collaboration-for-three-indications-with-kira-pharmaceuticals\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/koru-medical-systems-announces-novel-therapy-collaboration-for-three-indications-with-kira-pharmaceuticals\\\/\",\"name\":\"KORU Medical Systems Announces Novel Therapy Collaboration for Three Indications with Kira Pharmaceuticals - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-11-08T12:02:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/koru-medical-systems-announces-novel-therapy-collaboration-for-three-indications-with-kira-pharmaceuticals\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/koru-medical-systems-announces-novel-therapy-collaboration-for-three-indications-with-kira-pharmaceuticals\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/koru-medical-systems-announces-novel-therapy-collaboration-for-three-indications-with-kira-pharmaceuticals\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"KORU Medical Systems Announces Novel Therapy Collaboration for Three Indications with Kira Pharmaceuticals\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"KORU Medical Systems Announces Novel Therapy Collaboration for Three Indications with Kira Pharmaceuticals - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/koru-medical-systems-announces-novel-therapy-collaboration-for-three-indications-with-kira-pharmaceuticals\/","og_locale":"en_US","og_type":"article","og_title":"KORU Medical Systems Announces Novel Therapy Collaboration for Three Indications with Kira Pharmaceuticals - Pharma Trend","og_description":"MAHWAH, N.J.–(BUSINESS WIRE)–KORU Medical Systems, Inc. (NASDAQ: KRMD) (\u201cKORU Medical\u201d or the \u201cCompany\u201d), a leading medical technology company focused on the development of innovative and easy-to-use subcutaneous infusion solutions, today announced the progression of its agreement with Kira Pharmaceuticals, including expansion into three important additional indications. Kira will utilize KORU Medical\u2019s Freedom System for Phase ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/koru-medical-systems-announces-novel-therapy-collaboration-for-three-indications-with-kira-pharmaceuticals\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-08T12:02:22+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/koru-medical-systems-announces-novel-therapy-collaboration-for-three-indications-with-kira-pharmaceuticals\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/koru-medical-systems-announces-novel-therapy-collaboration-for-three-indications-with-kira-pharmaceuticals\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"KORU Medical Systems Announces Novel Therapy Collaboration for Three Indications with Kira Pharmaceuticals","datePublished":"2022-11-08T12:02:22+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/koru-medical-systems-announces-novel-therapy-collaboration-for-three-indications-with-kira-pharmaceuticals\/"},"wordCount":367,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/koru-medical-systems-announces-novel-therapy-collaboration-for-three-indications-with-kira-pharmaceuticals\/","url":"https:\/\/pharma-trend.com\/en\/koru-medical-systems-announces-novel-therapy-collaboration-for-three-indications-with-kira-pharmaceuticals\/","name":"KORU Medical Systems Announces Novel Therapy Collaboration for Three Indications with Kira Pharmaceuticals - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-11-08T12:02:22+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/koru-medical-systems-announces-novel-therapy-collaboration-for-three-indications-with-kira-pharmaceuticals\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/koru-medical-systems-announces-novel-therapy-collaboration-for-three-indications-with-kira-pharmaceuticals\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/koru-medical-systems-announces-novel-therapy-collaboration-for-three-indications-with-kira-pharmaceuticals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"KORU Medical Systems Announces Novel Therapy Collaboration for Three Indications with Kira Pharmaceuticals"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50603","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50603"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50603\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50603"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50603"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50603"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}